Abivertinib
Abivertinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase JAK3, epidermal growth factor receptor, and tyrosine-protein kinase BTK.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | 5 | 4 | 2 | — | — | 9 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 | |
Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell lymphoma | D016393 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ABIVERTINIB |
INN | abivertinib |
Description | Abivertinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase JAK3, epidermal growth factor receptor, and tyrosine-protein kinase BTK. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors: epidermal growth factor receptor (EGFR) inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1 |
Identifiers
PDB | — |
CAS-ID | 1557267-42-1 |
RxCUI | — |
ChEMBL ID | CHEMBL4297865 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | CER0OPG92L (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
JAK3
JAK3
EGFR
EGFR
BTK
BTK
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 90 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,020 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more